Avexxin AS
Records under this name other than the patents Avexxin AS holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,085,953 | Skin Cancer Treatment Lapsed on the fee record Ended Oct 2, 2026 · High confidence | Lapsed on the fee record | Ended Oct 2, 2026 | High confidence |
| US 11,439,625 | Combination Therapy for Proliferative Diseases Lapsed on the fee record Ended Sep 13, 2026 · High confidence | Lapsed on the fee record | Ended Sep 13, 2026 | High confidence |
| US 8,796,251 | Compositions and Methods for the Treatment of Glomerulonephritis Lapsed on the fee record Ended Aug 5, 2026 · High confidence | Lapsed on the fee record | Ended Aug 5, 2026 | High confidence |
| US 11,351,127 | Pharmaceutical composition Lapsed on the fee record Ended Jun 7, 2026 · USPTO record | Lapsed on the fee record | Ended Jun 7, 2026 | USPTO record |
| US 10,953,004 | Combination therapy for proliferative diseases Lapsed on the fee record Ended Mar 23, 2025 · USPTO record | Lapsed on the fee record | Ended Mar 23, 2025 | USPTO record |
| US 9,597,318 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders Lapsed on the fee record Ended Mar 21, 2025 · USPTO record | Lapsed on the fee record | Ended Mar 21, 2025 | USPTO record |
| US 10,851,114 | 2-oxothiatole compounds having activity as cPLA2 inhibitors for the treatment of inflammatory disorders and hyperproliferative disorders Lapsed on the fee record Ended Dec 1, 2024 · USPTO record | Lapsed on the fee record | Ended Dec 1, 2024 | USPTO record |
| US 10,758,499 | Dermatitis treatment Lapsed on the fee record Ended Sep 1, 2024 · USPTO record | Lapsed on the fee record | Ended Sep 1, 2024 | USPTO record |
| US 9,187,396 | Compositions and Methods for the Treatment of Glomerulonephritis Lapsed on the fee record Ended Nov 17, 2023 · High confidence | Lapsed on the fee record | Ended Nov 17, 2023 | High confidence |
| US 8,865,768 | Use of polyunsaturated ketones for the treatment of psoriasis Term ended Ended no later than Jan 29, 2023 · USPTO record | Term ended | Ended no later than Jan 29, 2023 | USPTO record |